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Abstract
Background: The stromal vascular fraction (SVF) derived from adipose tissue contains adipose-derived stromal/stem
cells (ASC) and can be used for regenerative applications. Thus, a validated protocol for SVF isolation, freezing, and
thawing is required to manage product administration. To comply with Good Manufacturing Practice (GMP), fetal
bovine serum (FBS), used to expand ASC in vitro, could be replaced by growth factors from platelet concentrates.
Methods: Throughout each protocol, GMP-compliant reagents and devices were used. SVF cells were isolated from
lipoaspirates by a standardized enzymatic protocol. Cells were cryopreserved in solutions containing different
albumin or serum and dimethylsulfoxide (DMSO) concentrations. Before and after cryopreservation, we analyzed:
cell viability (by Trypan blue); immunophenotype (by flow cytometry); colony-forming unit-fibroblast (CFU-F)
formation; and differentiation potential. ASC, seeded at different densities, were expanded in presence of 10% FBS
or 5% supernatant rich in growth factors (SRGF) from platelets. The differentiation potential and cell transformation
grade were tested in expanded ASC.
Results: We demonstrated that SVF can be obtained with a consistent yield (about 185 × 103 cells/ml lipoaspirate)
and viability (about 82%). Lipoaspirate manipulation after overnight storage at +4 °C reduced cell viability (−11.6%).
The relative abundance of ASC (CD34+CD45−CD31–) and endothelial precursors (CD34+CD45−CD31+) in the SVF
product was about 59% and 42%, respectively. A period of 2 months cryostorage in autologous serum with added
DMSO minimally affected post-thaw SVF cell viability as well as clonogenic and differentiation potentials. Viability
was negatively affected when SVF was frozen at a cell concentration below 1.3 × 106 cells/ml. Cell viability was not
significantly affected after a freezing period of 1 year.
Independent of seeding density, ASC cultured in 5% SRGF exhibited higher growth rates when compared with 10%
FBS. ASC expanded in both media showed unaltered identity (by flow cytometry) and were exempt from genetic
lesions. Both 5% SRGF- and 10% FBS-expanded ASC efficiently differentiated to adipocytes, osteocytes, and chondrocytes.
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Conclusions: This paper reports a GMP-compliant approach for freezing SVF cells isolated from adipose tissue by a
standardized protocol. Moreover, an ASC expansion method in controlled culture conditions and without involvement of
animal-derived additives was reported.
Keywords: Stromal vascular fraction, Adipose tissue, Freezing protocol, Cell viability, CFU-F, Immunophenotype
characterization, Adipose stem/stromal stem cells, Growth rate, Differentiation potential, Cell morphology, Karyotype,
Anchorage independent growth, Good manufacturing practice, Advanced therapy medicinal product
Background
Adipose tissue, beside its role for energy storage, is a known
source of stromal precursors and stem cells. These cells are
enclosed in the so-called stromal vascular fraction (SVF), a
heterogeneous population including hematopoietic cells,
and adipose-derived stromal/stem cells (ASC). Approaches
for the phenotypic characterization of SVF cells were previ-
ously suggested in position papers from the International
Federation for Adipose Therapeutics and Science (IFATS)
and from the International Society of Cellular Therapy
(ISCT), as well as in other publications [1–3]. Such a com-
posite and heterogeneous pool of cells can be used for clin-
ical applications by virtue of the pro-angiogenetic and
immune modulatory activity exerted by the different cell
populations [1, 2]. SVF can be extracted from lipoaspirates
by enzymatic digestion, followed by filtration and cell wash-
ing [4]. The possibility of storing purified SVF products by
cryopreservation and freezing is crucial to optimize the
study design for clinical applications in humans. Successful
SVF cryopreservation using different protocols has been
demonstrated in previously published works [3, 5] but there
is not clear consensus about the appropriate freezing ap-
proach that maximally preserves cell viability.
In recent years, stromal cells have been utilized in a
growing number of trials for different clinical applications
[6]. SVF derived from adipose tissue is an abundant source
of ASC [7, 8]. IFATS/ISCT proposed three minimal
criteria for the definition of ASC: 1) plastic adherence; 2)
expression of CD73, CD90, and CD105, and lack of ex-
pression of CD11b, CD14, CD19, CD45, and HLA-DR;
and 3) differentiation potential into adipocytes, chondro-
cytes, and osteoblasts [9, 10]. Ex-vivo cell expansion must
be performed to obtain a sufficient number of cells for po-
tential use in humans; such “extensive manipulation” is
subject to Advanced-Therapy Medicinal Product (ATMP)
regulations [11]. ATMPs must be produced in compliance
with current Good Manufacturing Practice (GMP) guide-
lines. As well as strict requirements concerning the pro-
duction facilities (cell factories, personnel, procedures),
GMP guidelines also regulate the quality of reagents and
disposables used in the manufacturing process. Fetal
bovine serum (FBS) is a well-known growth supplement
for cell culture, but xeno-carbohydrates and xeno-proteins
contained in FBS may lead to undesired clinical effects
[12–15]. Thus, since 2001, replacement of FBS with suit-
able alternatives has been recommended for GMP-grade
cell expansion throughout Europe and the United States
[16]. The use of human growth factors derived from plate-
lets for ex-vivo stem cell expansion is compliant with
GMP guidelines [17–20]. In previous publications, growth
factor release from platelets was obtained by repeated
freeze and thaw cycles [18, 21–24]. In this work, we used
a supernatant rich in growth factors (SRGF) produced, as
previously published [25], through CaCl2 addition to the
platelet apheretic product from healthy donors. SRGF final
batches used in this work were manufactured by pooling
together a number of single-donor products that has been
shown to reduce the variability of growth factor concen-
trations [26]. The impact on mesenchymal stem cell pro-
liferation and differentiation mediated by growth factors
derived from platelets through CaCl2 addition has been
previously investigated [17, 27, 28] but it is still not fully
characterized. Furthermore, there is limited knowledge
about the influence of SRGF on ASC physiology in cell
culture. Noteworthy, in this paper, the SRGF-mediated ef-
fect on the ASC growth rate was assessed by seeding cells
at different densities; the effect of plating density on cell
physiology has been previously investigated only on mes-
enchymal stem cells derived from murine [29] or human
[30–32] bone marrow. In this work, we aimed to define
an efficient GMP-compliant method to cryopreserve SVF
cells isolated from adipose tissue and to expand ASC
using SRGF as medium additive, starting from a thawed
SVF product. In particular, we investigated the impact of
different cryopreserving solutions on viability, immuno-
phenotype, clonogenicity, and differentiation capacity of
nucleated cells (NC) or ASC enclosed in SVF. In addition,
ASC were expanded at different cell seeding densities in
10% FBS- or 5% SRGF-containing media. We determined
the impact of different culture conditions on the ASC
expansion rate, immunophenotype, and differentiation
potential. GMP-compliant materials, reagents, and de-
vices were used.
Methods
Description of the study
This study obtained approval from the Ethics Committee
of the CRO Aviano National Cancer Institute (protocol
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number: CRO-2016-30), and it was carried out in ac-
cordance with the Declaration of Helsinki (2004).
In this study, 19 leftover lipoaspirates were processed
for SVF extraction, with 14 lipoaspirates being taken
from the abdomen and the remaining samples from the
thigh or hip/flank. The first six lipoaspirates were imme-
diately treated after delivery to the cell-processing la-
boratory from the operating theatre, while the others
were left at +4 °C for 16–18 h (overnight) before ma-
nipulation. Cell count and viability assay were performed
immediately after SVF isolation. To optimize the proto-
col of such quality control test, the impact of performing
red blood cell lysis before cell viability evaluation was
tested in paired aliquots of the first four SVF products.
Immunophenotypic analysis of SVF cells before cryo-
preservation was performed in nine SVF. Cryopreserva-
tion was performed using four different solutions. Due
to limited availability of extracted SVF cells, simultan-
eous application of all four cryopreservation methods to
each product was not possible; thus, solutions A and B
were used in 10 out of 19 SVF, solution C in 9 out of 19
SVF, and solution D in 5 out of 19 SVF. The compos-
ition of each solution is described below. Cell viability
was measured again in all SVF products upon thawing
after 2 months of storage. Further investigations were
performed on five SVF products cryopreserved by solu-
tions C and D, in which we evaluated immunopheno-
type, colony forming unit-fibroblasts (CFU-F) growth,
and differentiation potential. Moreover, three aliquots of
these SVF products were used to assess viability upon
thawing after 1 year of storage. The same five SVF sam-
ples that were thawed after 2 months of storage were
placed in culture to extract and expand the ASC. We de-
fined the impact of the cell seeding density on ASC
growth rate in both 5% SRGF- or 10% FBS-containing
media. Moreover, we tested the effect of the different
media on ASC morphology, immunophenotype, differen-
tiation potential, transformation, and karyotype stability.
SVF isolation from adipose tissue
Lipoaspirates were derived from 19 female breast cancer
patients (age 52.4 ± 1.6 years, body mass index 23.5 ± 2.4
kg/m2) who underwent quadrantectomy or total
mastectomy and reconstructive lipotransfer. Fat tissue
was harvested under local anesthesia by standard sterile
liposuction techniques as described by Coleman [33, 34].
All samples were waste byproducts of surgery. SVF
isolation was performed according to a previously
published protocol [8] with modifications. Under a
laminar flow biological cabinet, the lipoaspirate was
transferred to a plastic bag (Transfer Bag, JMS
Singapore PTE LTD, Singapore) and washed three times
by adding warm (37 °C) clinical-grade Ringer Lactate so-
lution (S.A.L.F. S.p.A. Laboratorio Farmacologico,
Bergamo, Italy). After phase stratification, the lower
phase was discarded. Thereafter, a solution of collage-
nase, 0.15 U/ml final concentration (NB 6 Good Manu-
facturing Practice grade, SERVA Electrophoresis GmbH,
Heidelberg, Germany) was added to the washed lipoaspi-
rate. The product was incubated for 60–70 min at 37 °C
in a certified medical device (Plasmatherm Barkey
GmbH & Co KG, Leopoldshoehe, Germany). The strati-
fication (Fig. 1a) was considered to indicate complete
lipoaspirate digestion. After collagenase neutralization
by the addition of a human albumin solution (Albital
200 g/l, Kedrion S.p.A., Lucca, Italy) and product stratifi-
cation, the lower phase was recovered and centrifuged at
400 × g for 10 min at +4 °C. The cell pellet was washed
with a solution composed of 10% Albital, 10% Anti-
coagulant Acid Citrate Dextrose Solution–A (ACD-A;
Haemonetics Corporation, Braintree, MA, USA), and
2 U/ml heparin (Epsodilave, HOSPIRA ITALIA S.r.l.,
Napoli, Italy) in Ringer Lactate solution.
SVF cell count and viability analysis
Cell counts were performed using a Burker chamber. To
estimate the total NC content, a small aliquot of the SVF
final product was stained with 5% crystal violet dye
(Sigma, St. Louis, MO, USA). SVF cell viability was esti-
mated by Trypan blue dye exclusion test; an aliquot of the
cell product was added to 0.4% Trypan blue dye (0.2%
final concentration) (European Pharmacopeia 7.0, 2011).
Only NC with an approximate circular shape were taken
into account and, among these, only markedly colored
cells were considered to be dead cells. In part of the
a
b
Fig. 1 a Distinct stratified phases are clearly evident after 1 h of
lipoaspirate treatment with collagenase solution at 37 °C. Stromal
vascular fraction cells are contained in the lower clear phase; digested
adipocytes as well as released oily lipids are stratified in the two upper
phases. The image is representative of a completely accomplished
digestion process. b Images of diluted stromal vascular fraction cells
cytospun on a glass slide. Cells were differentially stained by May-Grunwald/
Giemsa protocol. Scale bar =10 μm
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samples, cell counts were performed by three independent
and skilled operators to test the reliability of the per-
formed evaluations; obtained data were correlated and
consistent (data not shown).
Cell viability was calculated as follows: percent NC via-
bility = viable NC / total NC × 100. For cell imaging pur-
poses, an aliquot of SVF samples was diluted and
cytospun by a standard protocol on a glass slide.
Elimination of red blood cells from the specimen can
facilitate microscopic evaluation of NC. Red blood cell
lysis cannot be performed on the cellular product ad-
ministered to the patient since a GMP-grade lysis solu-
tion is not available: thus, features of the lysed biological
specimen could be different from the product aimed to
be administered to the patient. In this work, we tested
the impact on NC viability results mediated by perform-
ing red blood cell lysis immediately before Trypan blue
dye exclusion test. On a small aliquot of selected SVF
products, lysis solution (PharmLyse, BD Biosciences,
Becton-Dickinson, San Jose, CA) was added (5 min in
wet ice) before cell staining with Trypan blue dye. In
parallel, NC viability was evaluated in the same paired
SVF products by Trypan blue dye staining, without the
addition of lysis solution. In part of the SVF fresh sam-
ples, cells were cytospun and differentially stained by the
May-Grunwald/Giemsa protocol. Images were taken by
a digital color camera (Motic) (Fig. 1b).
Immunophenotypic characterization of SVF and ASC by
flow cytometry
After lysis of residual erythrocytes in PharmLyse solu-
tion (BD Biosciences), cells were washed, maintained in
BD Pharmingen Stain Buffer, and labeled with a large
panel of monoclonal antibodies (all from BD Biosci-
ences): CD34 APC or PE-Cy7, CD45 APC-Cy7 or FITC,
CD31 FITC, CD90 FITC or APC, CD73 PE, CD13 APC,
CD44 FITC, CD29 APC, CD166 PE, CD10 PE or APC,
HLA I/ABC PE, HLA II/DR FITC, CD106 PE, CD36
FITC, CD146 PE, CD235 (Glyα) PE, CD144 PE, CD11b
APC, CD11c APC, CD14 APC, and CD105 PE
(Beckman Coulter). Labeling was performed while keep-
ing in each tube CD34 (clone 581), CD45, and 7-
aminoactinomycin D (7-AAD; to discriminate dead
cells). Glyα was used to confirm the exclusion of residual
red blood cells from the analysis. In some cases, the SVF
sample was labeled as received without lysis or washing,
and Hoechst was added to the labeling combination in
order to stain nuclei and confirm the gating strategy
(data not shown).
Samples were acquired on a BD FACSCanto II flow cyt-
ometer and analyzed by BD Diva software. All experiments
were performed after instrument calibration with CS&T
beads (BD Biosciences). A multicolor gating strategy ana-
lysis was performed, excluding debris (using residual
lymphocytes as an internal standard), and dead cells (based
on 7-AAD), focusing on live intact cells [35]. CD34-
positive (+) cells were gated and deeply characterized for
expression of CD31 and subsequently of the other
markers. Among the CD34-negative(–) cells, the CD45+
fraction was identified as residual white blood cells.
Aliquots of ASC, expanded at the seeding density of
1 × 103 cells/cm2 in media with 10% FBS or 5% SRGF
added for different cell passages (see below), were
detached by trypsinization and washed in Pharmingen
Stain Buffer. Cells were labeled with the same panel of
monoclonal antibodies used for SVF.
Cryopreservation and freezing of SVF
Cryopreservation was performed by resuspending SVF
cell pellets in four different solutions. Solution A was
prepared by adding the following to the standard saline
solution (B. Braun, Melsungen, Germany): Albital (10%),
ACD-A (5%), and dimethylsulfoxide (DMSO; 10%;
CryoSure-DMSO, Li StarFish, Milan, Italy). Solution B
was prepared by adding the following to the saline solu-
tion (B. Braun): human serum (50%), Albital (5%), ACD-
A (2.5%), and DMSO (10%). Solution C and solution D
were prepared by adding DMSO at 10% and 5%, respect-
ively, to pure human serum. Thus, solutions A and B
contained the saline solution, the same amounts of
DMSO, and different concentrations of human serum,
Albital, and ACD-A. The serum-based solutions C and
D differed between each other only for the DMSO con-
centration, and they did not contain Albital or ACD-A.
Solutions A, B, and C contained the same amounts of
DMSO. Final concentrations were reported. Samples
were frozen overnight at −80 °C in freezing containers
designed to achieve a cooling rate of −1 °C/min (Mr
Frosty, Thermo Scientific, Waltham, MA, USA). After-
wards, samples were stored in liquid nitrogen vapor
phase (−190 °C).
SVF thawing
SVF aliquots were thawed at 37 °C for 2 min and, to com-
pletely remove DMSO, cells were resuspended in 8 ml
serum-free minimum essential medium eagle—alpha
modification (α-MEM; Lonza, Basel, Switzerland) contain-
ing 100 IU/ml penicillin and 100 mg/ml streptomycin
(both from Sigma) and were centrifuged at 260 × g for
5 min at room temperature. Serum-free medium was used
to avoid the influence of any medium additive on the fol-
lowing cell assays or expansion procedure.
CFU-F assay
The availability of fibroblast progenitors in fresh and
thawed SVF aliquots (cryopreserved by methods C and
D) was evaluated by CFU-F assay [9, 36, 37]. Cells were
then resuspended and seeded at a final concentration of
Agostini et al. Stem Cell Research & Therapy  (2018) 9:130 Page 4 of 16
5 × 102 NC/cm2 in complete α-MEM. Complete α-MEM
was obtained by adding 100 IU/ml penicillin, 100 μg/ml
streptomycin (both from Sigma), and 10% vol/vol FBS
(Lonza). Six-well plates (BD Biosciences, Bedford, MA,
USA) were incubated at 37 °C under 5% CO2. After
24 h, the supernatant medium containing nonadherent
cells was removed and discarded. After a single wash
with phosphate-buffered saline (PBS; Lonza, Basel,
Switzerland), fresh complete α-MEM containing 10%
FBS was replaced on adherent cells. After 14 days, cells
were washed with PBS, fixed with methanol, and stained
by 5% vol/vol crystal violet (both from Sigma). Colonies
were evaluated under an inverted phase-contrast micro-
scope (Olympus CKX41, Olympus Italia Srl, Milano,
Italy). Aggregates of more than 50 cells were considered
as colonies.
SVF differentiation potential assay
To assess the differentiation potential of freshly extracted
or thawed SVF aliquots cryopreserved by methods C and
D the following procedure was applied. SVF cells were re-
suspended in complete α-MEM containing 10% FBS and
then cells were seeded at 5 × 104 NC/cm2 in standard T25
tissue culture flasks (BD Biosciences). After 24 h,
nonadherent cells were removed. After a single wash with
PBS, α-MEM containing 10% FBS was replaced on adher-
ent cells. After 7 days, cells were detached by trypsin-
ethylenediaminetetraacetic acid (EDTA; TrypLe Select
10X, Life Technologies-Thermo Fisher Scientific,
Waltham, MA, USA) and counted using a Cellometer
Auto M10 (Nexcelom Bioscience, Lawrence, MA, USA).
Adipogenic, chondrogenic, and osteogenic differentiations
were achieved using StemMACS AdipoDiff, ChondroDiff,
and OsteoDiff media (Miltenyi Biotec GmbH, Bergisch
Gladbach, Germany) following the manufacturer’s instruc-
tions. After 21 days, adipocytes, chondrocytes (spheroids),
and osteocytes were stained by Oil Red-O, Safranin-O,
and Alizarin Red (Sigma), respectively. Osteogenic and
adipogenic differentiation was analyzed by staining quanti-
fication in captured images using MATLAB® (Mathworks,
Natick, MA, USA) software. After background subtrac-
tion, results were expressed as the percentage covered
area. Chondrogenic differentiation was quantified measur-
ing spheroid size taking advantage of Motic Images Plus 2.
0 software®. Spheroid volume was calculated using the for-
mula: (width2 × length × 3.14) / 6 [38].
SRGF production
Platelet concentrates were obtained as previously pub-
lished [25] with minor modifications. Briefly, samples of
platelet concentrates were obtained from washouts of
leukocyte depletion filters intended for disposal, taken
from platelet apheresis collection kits (Haemonetics
MCS+ System; Haemonetics, Signy-Centre, Switzerland)
after donation from healthy donors. Under a sterile bio-
logical safety hood, the filtered apheretic product was
transferred to a sterile tube (BD Biosciences). Platelet ac-
tivation was performed by the addition of CaCl2 at a
final concentration of 0.04 M (Monico SPA, Venice,
Italy) and by incubation at 40 °C for approximately
60 min, i.e., until complete clot formation. Supernatants
of centrifuged samples were stored at −80 °C until ana-
lysis. To obtain SRGF batches containing consistent
amounts of growth factors we created pools of 16 single-
donor SRGF products [26]. The obtained product was
filtered through a 0.22-μm mesh filter (Merk Millipore,
Darmstadt, Germany). Sterility tests were performed by
standard procedures. Two separate batches were utilized
in the present work.
Ex-vivo expansion of ASC from thawed SVF cells
Thawed SVF cells were separately plated in standard T25
tissue culture flasks (BD Biosciences) with complete α-
MEM medium plus 10% vol/vol FBS and in parallel with
5% vol/vol SRGF. SRGF was used at 5% as we previously
demonstrated that further increasing the SRGF concentra-
tions failed to confer any relevant advantages in terms of
the ASC proliferation rate [28]. Cells, seeded at a cell
density of 5 × 104 NC/cm2, were allowed to adhere for
24 h. Nonadherent cells were then removed, and fresh
medium was added after a single wash with PBS. Upon
80–90% confluence, cells (considered to be ASC) were
detached by trypsin-EDTA. Resuspended cells were
seeded (at passage (P)1 and at each following cell passage)
at four different densities: 1 × 102 cells/cm2, 1 × 103 cells/
cm2, 5 × 103 cells/cm2, and 1 × 104 cells/cm2. At each
passage, the theoretical cell yield (TCY) was calculated.
The following equations were applied: TCY at Pi = n1i
× e[ln(2)/PDTi], where PDTi = (tPi – tPi-1) × 24/PDN at
Pi. (tPi – tPi-1) × 24 is the time interval (in hours) be-
tween consecutive cell passages, and PDN at Pi = 3.32 ×
(log n2i – log n1i). n1i is the number of seeded cells and
n2i is the number or harvested cells at the selected pas-
sage (Pi). When only part of the harvested cells were
seeded, the following equation was applied: TCY at Pi =
TCY at Pi–1 × e[ln(2)/PDTi].
ASC expanded in α-MEM medium plus 10% vol/vol
FBS or 5% SRGF were considered to be at low passages at
P2–P3 [39]. ASC expanded in α-MEM medium plus 10%
vol/vol FBS were considered to be at high passages when
between P7 and P9 [39]. Otherwise, a posteriori consider-
ing the expansion rate of ASC expanded in α-MEM
medium plus 5% vol/vol SRGF, such cells were considered
to be at high passages when between P12 and P14.
Morphometric analysis of expanded ASC
Images of high and low passage ASC expanded in
α-MEM medium plus 10% vol/vol FBS or with 5% vol/
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vol SRGF were taken 24–48 h after seeding at 1 × 103
cells/cm2 by phase-contrast microscopy (Olympus) and
digital color camera (Motic). Morphometric analysis was
performed taking advantage of Motic Images Plus 2.0
software® after appropriate calibration. At least 60 cells
per captured image were manually analyzed. Measures
of the cell major and minor axes as well as cell area were
quantified using appropriate software tools following the
manufacturer’s protocol.
ASC differentiation potential assay
Adipogenic, chondrogenic, and osteogenic differentiation
potential was assayed at high and low passages in ASC ex-
panded by complete 10% FBS or 5% SRGF media at the
plating density of 1 × 103 cells/cm2. Cells were detached
by trypsinization, and adipogenic, chondrogenic, and
osteogenic differentiations were achieved utilizing
StemMACS AdipoDiff, ChondroDiff, and OsteoDiff media
(Miltenyi Biotec GmbH). After 21 days, osteocytes,
adipocytes, and chondrocytes (spheroids) were stained by
Oil Red-O, Safranin-O, and Alizarin Red (Sigma), respect-
ively. Cell images were taken by inverted phase-contrast
microscope (Olympus) and digital color camera (Motic).
Osteogenic and adipogenic differentiation was analyzed by
staining quantification in captured images using
MATLAB® (Mathworks) software. After background sub-
traction, results were expressed as the percentage of cov-
ered area. Chondrogenic differentiation was quantified
measuring spheroid size taking advantage of Motic Images
Plus 2.0 software®. Spheroid volume was calculated using
the formula: (width2 × length × 3.14)/6 [38].
Cell transformation assay
ASC expanded until high passages in complete 10%
FBS or 5% SRGF media at 1 × 103 cells/cm2 were
detached by trypsinization, and resuspended in serum-
free α-MEM plus 100 IU/ml penicillin and 100 μg/ml
streptomycin. A total of 4 × 103 cells resuspended in
200 μl medium were further diluted with 1 ml of a
methylcellulose-based medium (MethoCult H4230,
StemCell Technologies, Vancouver, BC, Canada) [40].
After repeated resuspension by syringe (BD Biosci-
ences) equipped with a blunt-end needle, cells were
plated (in duplicate) in two wells of a 24-well plate (BD
Biosciences). After 14 days, colony formation was
checked by inverted microscope. Aggregates containing
at least 50 round-shaped cells clearly distinguishable
from underlying adherent cells were considered as col-
onies. HT1080 sarcoma cells (used as a positive con-
trol) were expanded in complete α-MEM plus 10% FBS,
according to standard cell culture protocols. Images
were taken by inverted phase-contrast microscope
(Olympus) and digital color camera (Motic).
Karyotype analysis
ASC expanded until high passages in complete 10% FBS
or 5% SRGF media at 1 × 103 cells/cm2 were detached by
trypsinization. When a consistent fraction of proliferating
round-shaped cells was evident on phase-contrast micros-
copy, karyotype analysis was performed according to
standard procedures [41]. Captured images of metaphasic
chromosomes were analyzed by CytoVision® software
(Leica, Wetzlar, Germany). At least 20 metaphases were
analyzed for each cell type.
Statistics
Data are presented as mean ± SEM. Paired or unpaired
Student’s t tests were applied to compare mean cell via-
bility in the SVF product before freezing (Trypan blue
exclusion test vs 7-AAD test; immediate vs delayed
lipoaspirate manipulation; with vs without addition of
red blood cell lysis solution). The impact of the different
cryopreserving solutions on SVF cell viability upon
thawing was analyzed by one-way analysis of variance
(ANOVA) for independent samples. Impact of longer
term cryostorage on SVF samples was analyzed by
ANOVA for repeated measures. Tukey’s honestly differ-
ent significance (HSD) with Bonferroni’s correction was
chosen as a post-hoc test. Significance of the difference
between means in a posteriori identified “High” and
“Low” groups was tested by unpaired Student’s t test.
Linearity of growth curves was tested calculating R2 as a
measure of goodness of fit of linear regression.
Differences between regression coefficients (slopes) of
growth curves were tested by the Regression Model
Analysis Test. Differences in cell morphology were
analyzed by ANOVA for independent samples with
interaction with Tukey’s HSD with Bonferroni’s
correction as a post-hoc analysis.
Results
SVF cell characterization before freezing
The mean volume of lipoaspirates was 66.8 ± 4.7 ml.
SVF mean cell yield evaluated at the end of the extrac-
tion protocol (before freezing) was 185.4 ± 19.3 × 103
NC/ml lipoaspirate. We also evaluated cell viability by
Trypan blue dye exclusion test in the fresh SVF and, as
displayed in Fig. 2a, NC viability measured in a subset of
fresh SVF aliquots treated by red blood cell lysis solution
was significantly (p < 0.01) lowered when compared with
matched untreated SVF aliquots (77.1 ± 3.9% vs 66.3 ± 4.
9%). Figure 2b shows that the mean NC viability
(measured without red blood cell lysis) in SVF extracted
from lipoaspirates stored for 16–18 h at +4 °C was
significantly (p < 0.01) decreased when compared with
immediately processed samples (82.2 ± 1.8 vs 70.6 ± 2.1).
Freshly isolated SVF samples were processed for
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cytofluorimetric analysis. The mean NC viability
evaluated through 7-AAD was 72.2 ± 7.6%.
Immunophenotypic characterization was performed
adopting a multicolor strategy that allowed identification
of different vital cell populations. In particular, as shown
in Fig. 3a, we identified in the CD34+CD45− population
(58.1 ± 7.6% of NC) a CD34++CD31−SSChigh subset (ASC,
putative adipose-derived stromal cells; 58.8 ± 16.6% of
CD34+ cells) and a CD34+CD31+SSClow subset (EPC,
putative endothelial progenitor cells; 43.2 ± 16.6% of
CD34+ cells).
The phenotype of CD34+ cells, and in particular of
ASC, was then characterized in detail with a large panel
of antibodies, as reported in Table 1 (part A) and in part
shown in Fig. 3b. ASC were brightly positive for CD90
and CD73, positive for CD13, CD44, CD10, and HLA I/
ABC, dimly positive for CD105, CD29, CD166, CD106,
and CD146, and negative for CD36, CD144, CD11c,
CD11b, CD14, Glyα, and HLA II/DR.
As shown in Fig. 3, when compared with ASC, the EPC
subset CD34+CD31+SSClow expressed CD90 and CD73
less brightly, but it was characterized by higher expression
of CD105 and CD146. EPC cells were CD13−. When
compared with ASC, the EPC population expressed
higher levels of CD144, CD36 and HLA II/DR, CD44 and
CD10, while the expression level of the remaining
markers was not different from ASC (data not shown).
Among the CD34− cells, we distinguished a CD34−CD45+
cell population of putative hematopoietic origin (32.5 ± 14.
6% of NC) and a CD31−CD45−CD146+ small subset
considered as pericytes (Fig. 3b). Overnight lipoaspirate
storage at +4 °C before SVF isolation did not affect the
expression pattern of NC immunophenotype markers.
Impact of freezing on SVF cells
Cells were cryopreserved at the mean final concentration
of 1.43 ± 0.7 × 106 NC/ml in the different cryopreserving
solutions (A, B, C, and D; see methods). The impact of
cryopreservation on SVF mononuclear cell viability
measured (upon thawing) by Trypan blue dye exclusion
test is shown in Fig. 4a. Statistical analysis showed that
post-thaw NC viability in SVF aliquots frozen for 2 months
with both solutions A and B was significantly (p < 0.01)
lower when compared to the viability measured in SVF
before freezing. Otherwise, cell cryopreservation by solu-
tions C and D fully prevented the loss of cell viability after
freezing. In addition, no significant differences in post-
thaw NC viability could be observed when comparing so-
lution C with solution D. Since NC viability in SVF sam-
ples cryopreserved by solutions A and B was markedly
lower (−34.6 ± 4.9%) when compared with samples cryo-
preserved by solutions C and D, solutions A and B were
not considered as eligible for clinical applications. We
then investigated the impact of NC concentration in the
freezing mixture on post-thaw SVF cell viability. Cell via-
bility data obtained in thawed SVF samples after 2 months
of storage with solutions C and D were grouped together
and a posteriori stratified according to NC concentration
measured in each sample upon freezing (i.e., after resus-
pension in cryopreserving solution). Two groups were
identified across a defined threshold of 1.3 × 106 NC/ml:
the group (n = 10) showing significantly higher NC
concentration (1.95 ± 0.19 × 106 NC/ml, p > 0.05) was
defined as High, and the other group (n = 4) was defined
as Low (0.52 ± 0.12 × 106 NC/ml). As displayed in Fig. 4b,
mean post-thaw cell viability measured in the High group
(69.0 ± 3.2%) was significantly (p < 0.05) higher than in the
Low group (37.5 ± 7.7%). In parallel, we aimed to evalu-
ate thawed NC viability changes after a prolonged
cryopreservation period. NC viability measured after
1 year of storage in solutions C and D was not sig-
nificantly different when compared with viability re-
sults measured after 2 months of freezing (Fig. 4c).
The phenotype evaluated after short- and long-term
freezing (data not shown) was superimposable on that
obtained in fresh samples (Table 1).
a b
Fig. 2 a Impact of red blood cell (RBC) lysis on percent nucleated cell (NC) viability measures in SVF. b Impact of overnight lipoaspirate storage at
+4 °C on percent NC viability measured by Trypan blue dye exclusion test (without red blood cell lysis) in fresh SVF samples. *p < 0.01, vs without
RBC lysis (Student’s t test for paired data); §p < 0.05, vs immediate manipulation (Student’s t test for unpaired data)
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Functional characterization of SVF cells
Thawed SVF cells were seeded on a tissue culture
plastic surface and adherent putative ASC were
analyzed. As shown in Fig. 5, we demonstrated adipo-
genic, osteogenic, and chondrogenic differentiation of
adherent ASC cells (P1) before SVF freezing and after
cryopreservation with solutions C and D. Representa-
tive images of adipogenic, osteogenic, and chondro-
genic differentiation assays are reported in Fig. 5; as
further evidenced by analytical quantification, the two
cryopreservation methods did not affect the cell dif-
ferentiation potential. Representative images of CFU-F
colonies obtained in fresh SVF samples as well as in
SVF samples frozen by cryopreserving solutions C
and D are displayed in Fig. 5.
Ex vivo ASC expansion
We expanded ASC extracted from SVF thawed products
comparing, at different cell seeding densities, the effect
of media supplementation with 5% SRGF and 10% FBS
on the ASC proliferation rate. Figure 6a shows, in a
logarithmic scale, changes in TCY over time (days) mea-
sured by culturing cells in the presence of 5% SRGF or
10% FBS at different plating densities. When cultured in
the presence of 10% FBS or 5% SRGF, ASC seeded at
1 × 103 cells/cm2, 5 × 103 cells/cm2, and 1 × 104 cells/cm2
underwent several passages in culture without evidence
of growth rate reduction. When compared with 10%
FBS, 5% SRGF induced an overall higher ASC
proliferation rate independent of cell seeding density
(Fig. 6a). Considering the same cell culture medium,
slopes of growth curves (linear, R2 = 0.98 ± 0.01) were
not significantly affected by cell seeding densities at 1 ×
103 cells/cm2, 5 × 103 cells/cm2, or 1 × 104 cells/cm2.
Otherwise, when seeded at 1 × 102 cells/cm2 both in 10%
FBS and 5% SRGF media, growth arrest rapidly
occurred. In particular, ASC cultured in 10% FBS
underwent growth arrest at P1 in ASC derived from 2
a
b
Fig. 3 Representative flow cytometry immunophenotype analysis of SVF cells evaluated before freezing. a Gating strategy identifying three main
populations in the SVF: CD34+CD31−CD45− subset (ASC, red), CD45−CD34+CD31+ subset (EPC, green), and CD34–CD45+ subset (hematopoietic cells,
blue). Dead cells (7AAD+) were excluded. b A detailed CD34+ cell characterization, showing expression of CD13, CD105, CD73, and CD90 in ASC and
EPC. Pericytes were identified as CD34−CD45−CD31−CD146+ population (in violet). Lymphocytes are showed as reference (dark blue)
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out of 5 patients, at P3 in 2 out of 5, and P6 in the last
case. Similarly, when seeded at 1 × 102 cells/cm2 in
presence of 5% SRGF, growth arrest occurred at P1 in
ASC derived from 1 out of 5 patients, at P4 in 3 cases,
and at P6 in the last case. At the seeding density of 1 ×
102 cells/cm2, growth in isolated cell aggregates was
frequently observed (data not shown). Figure 6b shows
representative images of cultured ASC in 10% FBS- or in
5% SRGF-supplemented medium at P0, at low passages,
and at high passages. Morphometric analysis of plastic-
adherent ASC expanded in 5% SRGF or 10% FBS con-
taining media is reported in Fig. 6c; independent of cell
passage number, ASC expanded in 5% SRGF medium
were smaller than ASC expanded in 10% FBS medium
(p < 0.001). The cell culture method and the cell passage
number significantly interacted (p = 0.002) to modulate
adherent cell dimensions. Post-hoc analysis demon-
strated that the cell area of ASC cultured in 5% SRGF
medium was greater at high passages when compared
with P0 and low passage cells. Still, independent of
cell passage, ASC expanded in 5% SRGF medium
were more elongated than ASC expanded in 10% FBS
medium (p < 0.001). The effect of cell culture and cell pas-
sage number significantly interacted (p < 0.001) to modu-
late the adherent cell shape. Post-hoc statistical analysis
demonstrated that, when compared with ASC grown in
10% FBS medium, ASC expanded in 5% SRGF medium
maintained a greater axis ratio, especially at high passage.
The immunophenotype of ASC expanded in 10% FBS or
5% SRGF medium was analyzed both at early and late
passages. The panel of analyzed surface markers was sub-
stantially the same as that adopted to evaluate NC in SVF
samples, including markers suggested by IFATS/ISCT [9].
As shown in Table 1 (part B), cells expressed CD90,
CD73, CD13, CD105, CD29, and CD166 at high intensity,
were positive for CD10, CD44, and HLA-ABC, and were
negative for CD34, CD45, CD31, HLA-DR, CD106, CD36,
CD146, CD235, CD144, CD11b, CD11c, and CD14. More-
over, CD13, CD105, CD29, and CD166 were overex-
pressed in expanded ASC when compared with
nonexpanded ASC in SVF. CD34 expression was lost
along with expansion, as expected. The expression level of
the selected surface markers was stable from cell passage
P3, and was maintained until late passages, with no sub-
stantial differences between cells grown with 10% FBS or
5% SRGF (Table 1, part B). Representative images of the
differentiation potential of ASC expanded in 10% FBS or
5% SRGF at low and high cell passages are reported in Fig.
7. As also evidenced by analytical quantification, the
adipogenic, osteogenic, and chondrogenic differentiation
potential was shown to be not significantly affected when
comparing ASC expanded in 10% FBS and in 5% SRGF
containing media, both at high and low passages.
Chromosome number and structure were analyzed in ex-
panded ASC at high passage, and Fig. 8a shows examples
of the obtained karyograms. In all analyzed samples, at
least 20 metaphases were analyzed, and no clonal or re-
current chromosomal alterations could be identified.
Figure 8b shows representative images of colony for-
mation assays in methylcellulose medium performed on
high-passage ASC cultured in 5% SRGF- and 10% FBS-
containing media. In all the performed assays, ASC col-
ony formation on methylcellulose failed to be seen.
Discussion
In the present study, we describe a method to extract SVF
cells from lipoaspirates derived from breast cancer pa-
tients who underwent quadrantectomy or total mastec-
tomy and reconstructive lipotransfer. A total of 19
lipoaspirates were processed to reliably set up and define
Table 1 Expression level of surface markers analyzed in adipose
tissue-derived stem cells (ASC) present in the stromal vascular
fraction (SVF) and in expanded ASC
Markers Part A Part B
ASC in SVF Expanded ASC
Fresh Thawed 10% FBS 5% SRGF
CD34 ++ ++ – –
CD45 – – – –
CD31 – – – –
CD90 ++ ++ ++ ++
CD73 ++ ++ ++ ++
CD13 + + ++ ++
CD105 +− +− ++ ++
CD44 + + + +
CD29 +− +− ++ ++
CD166 +− +− ++ ++
CD10 + + + +
HLA I, ABC + + +− +−
HLA II, DR – – – –
CD106 +− +− – –
CD36 – – – –
CD146 +− +− – –
CD235 – – – –
CD144 – – – –
CD11b – – – –
CD11c – – – –
CD14 – – – –
Part A reports the expression levels of selected markers in the 34++ 31−SSChigh
ASC contained in fresh or thawed SVF samples
Part B reports the expression levels of the same markers in expanded ASC in
the presence of 10% fetal bovine serum (FBS) or 5% supernatant rich in growth
factors (SRGF) and alpha-minimal essential medium (α-MEM)
Expression levels are described as + and – considering unlabeled cells as reference
(see also Fig. 3): ++, bright expression; +, positive expression; +−, dim expression
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the isolation protocol. Furthermore, we identified a safe
method to cryopreserve and freeze SVF cells with minimal
impact on cell viability or clonogenic and differentiation
potential. Due to the limited amounts of extracted cells
from each lipoaspirate, we could apply the different cryo-
preservation approaches only to subgroups of SVF sam-
ples. Moreover, we investigated the impact on the ASC
proliferation rate, identity, differentiation potential, and
cell stability mediated by SRGF, considered as a GMP-
compliant medium additive for the expansion of ASC to
obtain an ATMP. For practical and technical reasons, in-
vestigations regarding in vitro expanded ASC were limited
to five SVF specimens as a starting product.
The mean quantity of NC extracted from lipoaspirates
as well as the variability of the cell extraction yield (coef-
ficient of variation, 42.5%) was in agreement with previ-
ous publications [3, 42]. Interindividual differences
between lipoaspirate donors could explain the observed
variability [3, 42]. To assay the SVF cell viability we uti-
lized the Trypan blue dye exclusion manual test, as sug-
gested by European Pharmacopeia [43]. Viability results
published in previous papers were higher [3, 42] or
comparable [5] when matched to our present data. Cell
viability data were sufficiently consistent since the coeffi-
cient of variation between collected results was 13.1%.
The presence of dead cells in fresh SVF products can be
ascribed to mechanical adipose tissue disruption during
the liposuction procedure, as well as to cell separation,
washing, and concentration steps along with the
isolation protocol [5]. In accordance with previous data
[44], we showed that overnight storage of lipoaspirates
at +4 °C exerts a mild detrimental effect on fresh SVF
cell viability. Evaluation of cell viability is a quality con-
trol test within the manufacturing process and, thus, the
biological specimen should at best represent the product
condition as administered to the patient. We avoided
red blood cells lysis, frequently used to facilitate evalu-
ation of cell viability, as such a procedure is not nor-
mally performed on the final product aimed at patient
administration. Due to extensive adipose tissue washing,
the occurrence of residual red blood cells in the final
product was minimized. Moreover, our results suggested
that the lysis procedure could cause an underestimation
of fresh SVF cell viability.
a
c
b
Fig. 4 a Impact of different cryopreservation solutions on percent nucleated cell (NC) viability in thawed SVF products after 2 months of storage
in liquid nitrogen. A, B, C and D are different cryopreservation solutions: solution A (10% Albital, 5% ACD-A, 10% DMSO, 75% saline solution), solution B
(50% human serum, 5% Albital, 2.5% ACD-A, 10% DMSO, 32.5% saline solution), solution C (90% human serum, 10% DMSO), solution D (95% human
serum, 5% DMSO). When compared with solutions C and D, the viability of NC stored for 2 months by solutions A and B was significantly lower. *p < 0.01,
vs C and D; NSa, not significantly different vs C and vs Pre (one-way ANOVA for independent samples). b Impact of total NC concentration on SVF freezing
on post-thaw cell viability. In the high NC concentration group (High), cell viability measured after thawing was significantly higher than in the low concen-
tration (Low) group. §p < 0.05, vs High Group (Student’s t test for unpaired data). c Impact of longer term cryostorage on SVF samples. NC viability
measured after 1 year of freezing was not significantly different when compared with results obtained after 2 months storage. *p < 0.01, vs Pre (one-way
ANOVA for independent samples). NSb, not significantly different vs 2 months (one-way ANOVA for repeated measures). Tukey’s honestly
different significance with Bonferroni’s correction as post-hoc test
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The characterization of the SVF cells was performed
through a multiparametric immunophenotype analysis
based on flow cytometry. Unfortunately, no unique single
markers have been found so far; therefore, the analysis of a
combination of markers is necessary to identify a cell sub-
set sharing the same function and phenotypic signature.
Results derived from the large panel of analyzed antigens
were consistent with the minimal criteria proposed in the
IFATS/ISCT position paper [9] and with previous reports
[45–47]. In particular, as shown in Fig. 3 and Table 1, we
identified a cell population CD34++CD31−CD45−,
previously defined [9, 48] as ASC with mesenchymal
phenotype, and a cell subset CD34+CD31+CD45− that we
can bona fide define as EPC. In addition, we could identify
a CD34−CD31−CD45−CD146+ small population that can
be putatively classified as pericytes [48]. The availability of
such cell populations in fresh and thawed SVF confirms
the possibility of applying this product in regenerative
medicine applications since ASC, pericytes, and
endothelial cells can synergistically cooperate to induce the
formation of new blood vessels in an optimal regenerative
microenvironment [2]. In this study, SVF aliquots were
frozen using different cryopreservation solutions; NC
viability was minimally affected in SVF samples
cryopreserved with solutions containing pure serum and
DMSO at both final concentrations of 5% and 10%. Thus,
as previously demonstrated [3, 5], DMSO concentrations
in pure serum can be reduced to 5% to correctly
cryopreserve SVF cells. Under such conditions, cell
viability in the frozen product was shown to be stable for
at least 1 year. In addition, we have further demonstrated
[3, 5] that SVF cells can be frozen in serum with 5% (and
10%) DMSO without affecting post-thaw CFU-F growth as
well as ASC differentiation capacity. Reducing DMSO gives
a significant advantage for clinical utilization of the thawed
product since DMSO is known to be cytotoxic. Our ap-
proach can be considered as potentially compliant with
GMP guidelines since animal-derived components were
not used, and certified products or disposables were used
for the manufacturing process. Moreover, we showed that
post-thaw cell viability can be strongly reduced when freez-
ing SVF at a cell concentration lower than 1.3 × 106 NC/
ml (putative threshold roughly corresponding to 1.0 × 106
viable NC/ml). The definition of limited cell concentration
for optimal freezing is crucially important for future
clinical applications.
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Fig. 5 Representative images of osteogenic, adipogenic, and chondrogenic differentiation assays as well as colony forming unit-fibroblast (CFU-F)
assays performed on stromal vascular fraction (SVF) cells before freezing or after 2 months of storage in the presence of cryopreservation solutions
(Sol.) C and D. Differentiation was induced (Stim.) by the addition of commercially available osteogenic, adipogenic, and chondrogenic differentiation
media to cells at passage P1. Unstimulated cells (Unst.; control) were cultured with 10% FBS medium. Within the chondrogenesis assay, spheroids failed
to be obtained from unstimulated cells. Differentiated cells as well as unstimulated samples were stained with Alizarin Red, Oil Red-O, and Safranin-O to
detect osteocytes, adipocytes, and chondrocytes, respectively. The differentiation degree was quantified by image analysis of cell staining (adipogenesis
and osteogenesis) or by morphometric analysis of spheroids (chondrogenesis); results are reported in histograms. Sample storage in the presence of
solutions C and D did not significantly affect cell differentiation potential. Scale bar = 100 μm. C.A., covered area; Vol., volume
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In the second part of this work, we aimed to optimize
the ASC expansion protocol. ASC expansion is
mandatory for cell therapy applications in humans. As
an ATMP, expanded ASC must be produced in compli-
ance with current GMP guidelines. FBS is progressively
replaced in cell cultures by growth factors derived from
human alternative sources [16] since xeno-carbohydrates
and xeno-proteins may lead to undesired clinical effects
[12–15]. Mesenchymal stem cells were previously ex-
panded in vitro in a serum-free medium with a mixture
of commercially available growth factors; nevertheless,
under such conditions, the expression of selected surface
markers was shown to be affected [49, 50]. Moreover,
utilization of a coating substrate allowing cell adhesion
is often required and the cost of media and reagents is
considerably high. Utilization of human platelet-derived
growth factors is compliant with GMP guidelines [17–
20, 25]. In previous publications, growth factors were
derived by repeated freeze and thaw cycles [18, 21–24].
Cells grown under such conditions showed morphology,
as well as proliferation, immunomodulation, and differ-
entiation potential, comparable with cells grown in FBS-
containing media [18, 51, 52]. In this study, we used
SRGF as standardized medium additive to stimulate ex-
vivo ASC proliferation [25, 28]. Knowledge on the im-
pact of such a medium additive on ASC physiology in
cell culture is limited. Ancillary product standardization
is suggested by GMP guidelines [21, 53] and, as we pre-
viously demonstrated, pooling together 16 single-donor
products allowed a satisfactory batch-to-batch
consistency [26]. Our results regarding cell growth kinet-
ics demonstrated that SRGF dramatically increased the
ASC proliferation rate when compared with FBS; this ef-
fect was demonstrated considering changes in cell yield
at different cell passages. The expansion rate of bone
marrow mesenchymal stem cells in the presence of
growth factors derived from CaCl2-activated platelets
was previously shown to be higher when compared with
standard FBS [17, 28]. In a recent work, we demon-
strated that, when compared with FBS and platelet lysate
a
b
c
Fig. 6 a Growth curves (logarithmic scale) of adipose tissue-derived stem cells (ASC) seeded at different cell densities (from 1 × 102 to 1 × 104 cells/
cm2) in culture medium containing 10% fetal bovine serum (FBS) or 5% supernatant rich in growth factors (SRGF). The presence of SRGF in the cell
culture induced a significantly higher growth rate when compared with FBS. b Plastic-adhering cells at P0 and after short-term (Low passage) or
longer-term (High passage) expansion in the presence of 10% FBS or 5% SRGF in the cell culture medium. Scale bars = 100 μm. c Cell morphometric
analysis. ASC expanded in 5% SRGF medium were smaller than those expanded in 10% FBS medium. The cell area of ASC cultured in 5% SRGF medium
was greater at high passage when compared with P0 and low-passage cells. ASC expanded in 5% SRGF medium were more elongated than ASC
expanded in 10% FBS medium during all culture phases. Linearity of growth curves was tested by calculating R2 as a measure of goodness of fit of linear
regression. Differences between regression coefficients (slopes) of growth curves were tested by a Regression Model Analysis Test. *p < 0.01, vs FBS. Error
bars of ASC growth curves could not be graphically reported in the diagram (logarithmic scale of y axis); the coefficient of variation regarding each plotted
(mean) value of theoretical cell yield was below 10%. Connectors in c link significantly different means (p < 0.001, ANOVA for independent samples with
interaction with Tukey’s HSD with Bonferroni’s correction as post-hoc analysis). MEM, minimum essential medium; SVF, stromal vascular fraction
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as medium additives, SRGF induced the highest prolifer-
ation rate also in bone marrow mesenchymal stem cells
[54]. In this study, we tested ASC growth kinetics at dif-
ferent seeding densities and, independent of cell media
composition, we showed that seeding cells at 1 × 103
cells/cm2 can represent an optimal choice to expand
ASC, reducing repeated exposures to trypsin while
obtaining a satisfactory final cell yield. However, in a
previous publication, ASC displayed changes in gene
expression profiles in relation to cell seeding density:
proliferation-related genes were highly expressed in cells
expanded at low density, whereas genes regulating
chemotaxis or differentiation properties were highly
expressed in ASC expanded at high density (5 × 103
cells/cm2) [55]. We demonstrated that ASC, rapidly
expanded in the presence of 5% SRGF at 1 × 103 cells/
cm2, were characterized by a satisfactory capacity to
differentiate into osteoblasts, chondrocytes, and
adipocytes. Cell morphology was previously associated
with proliferation rate and differentiation potential and,
in particular, small and spindle-shaped cells were recog-
nized as rapidly dividing cells, while bigger flatter ones
were considered as slowly replicating cells [56, 57].
Considering our cell morphology analysis, we demon-
strated that, when compared with FBS, the ASC ex-
panded in SRGF-containing medium were smaller at
early passages and generally more elongated. These re-
sults are in accordance with our data demonstrating a
higher ASC proliferation rate in the presence of SRGF,
even at extended cell passages.
To confirm the identity of ASC, a panel of surface
markers was analyzed considering the ISCT recommen-
dations [10]. The cell immunophenotype of ASC
expanded in 10% FBS or 5% SRGF medium was ana-
lyzed both at low and high passages, and the obtained
expression pattern of surface markers was substantially
in line with previous reports [1, 9, 10]. Moreover, from
the early passages, a pure and stable cell population
sharing the same surface marker expression profile was
detected for ASC expanded both in 10% FBS and 5%
SRGF medium. Furthermore, the antigen expression
level was not differently affected throughout the expan-
sion process. Moreover, no difference was demon-
strated when considering different cryopreserving
solutions (namely, solutions C and D) used to store the
SVF product (data not shown). As expected [1], when
Fig. 7 Representative images obtained from osteogenic, adipogenic, and chondrogenic differentiation assays performed on ASC after short-term
or longer-term expansion at 1 × 103 cells/cm2 in the presence of 10% fetal bovine serum (FBS) or 5% supernatant rich in growth factors (SRGF) in
the cell culture medium. The differentiation degree was quantified by image analysis of cell staining (adipogenesis and osteogenesis) or by morphometric
analysis of spheroids (chondrogenesis); results are reported in histograms. The differentiation potential was shown to be not significantly affected when
comparing ASC expanded in 10% FBS and in 5% SRGF-containing media, both at high and low passages. Scale bar = 100 μm. C.A., covered Area; MEM,
minimum essential medium; Vol., volume; Unst., unstimulated
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compared to nonexpanded ASC contained in the SVF,
CD34 expression was blunted in expanded ASC and
the expression level of CD13, CD105, CD29, and
CD166 was increased (Table 1, part B). Under our ex-
perimental conditions, ASC did not show the expres-
sion of CD36; this marker was also reported to be
negative in bone marrow mesenchymal stromal/stem
cells [45, 58]. Within the process of expansion, ASC
could potentially develop genetic instabilities [59], and
chromosomal alterations may lead to apoptosis or cell
death, and also to cell transformation [60]. In this
study, we analyzed the cell karyotype and no genetic le-
sions in ASC expanded at high passages in the presence
of both 5% SRGF and 10% FBS were seen. Transformed
cells normally gain the capacity to grow under
anchorage-independent conditions [61]. ASC expanded
in both SRGF- and FCS-containing media failed to
form cell colonies on methylcellulose [40]. In a previ-
ous work, ASC expanded in a xeno-free medium did
not display features of tumor transformation despite a
high proliferation rate [62]. Thus, considering our re-
sults, we can suggest that ASC expanded in 5% SRGF
medium can be considered as genetically stable. Never-
theless, only further controlled clinical studies will shed
light on the long-term tumor formation risk secondary
to cell therapy treatments with expanded ASC.
Conclusions
In conclusion, in this study we identified a safe and GMP-
compliant protocol to extract, freeze, and thaw NC
contained in SVF from adipose tissue. Freezing SVF ali-
quots at the appropriate cell concentration with a cryopre-
serving solution containing low (5%) DMSO
concentration in pure serum failed to affect cell viability
after short- and medium-term storage. The availability of
an appropriate extraction, freezing, and thawing protocol
is very important to manage the timing of product admin-
istration to patients. Afterwards, we provided a better de-
scription of the influence of SRGF as medium additive on
the fundamental features of expanded ASC in vitro.
Immunophenotype characterization and functional prop-
erties of such rapidly proliferating cells were in accordance
with published guidelines [9, 10] and expanded ASC were
not transformed. In this way, we defined a safe method to
obtain, by a GMP-compliant protocol, expanded ASC
from thawed SVF. This whole approach was set up in
order to be easily “translated” within an authorized GMP
manufacturing facility for the production of ATMPs.
a
b
Fig. 8 a Representative karyotypes of adipose tissue-derived stem cells (ASC) expanded at high passages in 10% fetal bovine serum (FBS)- or 5%
supernatant rich in growth factors (SRGF)-containing medium. At least 20 metaphases were analyzed and no clonal or recurrent chromosomal al-
terations could be identified. b Displays images taken from colony formation assays in methylcellulose medium performed on high-passage ASC
cultured in 5% SRGF- or 10% FBS-containing medium. ASC expanded utilizing both cell culture media failed to display colony formation. HT1080
fibrosarcoma cells were used as positive control (c+). Scale bar = 100 μm. MEM, minimum essential medium
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